As is often the case with cancer treatments, many patients are able to benefit from therapy for a time. Tumor activity ...

Targeted Oncology: For the community oncologist, the choice between niraparib and olaparib often comes down to the patient's molecular profile. In a pMMR/HRD-negative patient, what clinical markers ...

Please provide your email address to receive an email when new articles are posted on . Poly(ADP-ribose) polymerase, or PARP, inhibitors appeared associated with increased risk for secondary ...

Fallopian tube cancer, a rare gynecologic cancer, is gaining awareness due to its potential origin for many high-grade serous ovarian cancers. New diagnostics improve early detection and treatment, ...

Stenoparib is being evaluated in combination with temozolomide clinical benefit in relapsed Small Cell Lung CancerTrial is fully funded by ...

Metastatic breast cancer has a poor prognosis, but emerging targeted therapies are providing some progress in the treatment of the disease, explained Filipa Lynce, MD, medical oncologist at ...

A new adverse event has been reported for PARP inhibitor drugs used in the treatment of cancer: the risk of developing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), both of which ...

A new study published by Mayo Clinic researchers suggests that ovarian cancer cells quickly activate a survival response ...

Kristin E. Fleischmann-Rose, NP: Nadine, can you discuss what PARP [poly ADP ribose polymerase] inhibitors are and explain the rationale behind using this targeted therapy in patients with breast ...

The use of PARP inhibitors and I/O therapy is examined for the treatment of triple-negative breast cancer, and the MEDIOLA and SWOG S1416 trials are reviewed. The first cohort of the MEDIOLA trial ...

CHICAGO -- Men with homologous recombination repair (HRR)-deficient, metastatic, castration-sensitive prostate cancer (mCSPC) lived significantly longer without disease progression when they received ...

PARP inhibitors, used to treat patients with cancer of the breast, ovaries, prostate and pancreas, work by inducing persistent DNA gaps in tumor cells with BRCA1 and BRCA2 mutations. The discovery ...